KATHLEEN CORONA: Open Payments
NPI 1316293566 · SALINA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$405 in 24 payments from 10 companies in 2025. Trend: 2023 $789 · 2024 $414 · 2025 $405
Food & beverage: $405
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $106 |
| ABBVIE INC. | 5 | $104 |
| Amgen Inc. | 4 | $66 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| Novo Nordisk Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| PFIZER INC. | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: MOUNJARO, VRAYLAR, OTEZLA, Ozempic, CAPLYTA, QULIPTA, BEXSERO, PENMENVY.
Industry payments across KS — which companies pay providers there.
